Strides Pharma Science Share Price
Sector: Biotechnology & Drugs
829.85 -14.85 (-1.76%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
822.80
Today’s High
849.30
52 Week Low
412.71
52 Week High
901.75
826.80 -18.45 (-2.18%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
820.10
Today’s High
850.00
52 Week Low
394.20
52 Week High
901.90
Key Metrics
- Market Cap (In Cr) 7627.59
- Beta 0.77
- Div. Yield (%) 0.47
- P/B 3.05
- TTM P/E 18.46
- Peg Ratio 0.45
- Sector P/E 22.66
- D/E 0.01
- Open Price 841.45
- Prev Close 844.7
Strides Pharma Science Analysis
Price Analysis
-
1 Week-1.04%
-
3 Months26.93%
-
6 Month20.88%
-
YTD28.18%
-
1 Year101.83%
Risk Meter
- 54% Low risk
- 54% Moderate risk
- 54% Balanced Risk
- 54% High risk
- 54% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 2
- 2
- 2
- 2
Strides Pharma Science News
Stock to buy: This multibagger small-cap stock is Axis Securities' momentum pick
2 min read . 30 May 2025Stocks to buy: Rajesh Palviya of Axis Sec suggests these 3 shares for today
3 min read . 30 May 2025Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 30 May 2025Strides Pharma shares jump over 9% on announcing OneSource share listing date
1 min read . 23 Jan 2025Strides Pharma Science Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 4565.34
- Selling/ General/ Admin Expenses Total
- 862.76
- Depreciation/ Amortization
- 192.26
- Other Operating Expenses Total
- 919.8
- Total Operating Expense
- 3890.12
- Operating Income
- 675.21
- Net Income Before Taxes
- 486.92
- Net Income
- 3593.46
- Diluted Normalized EPS
- 38.14
- Period
- 2025
- Total Assets
- 6048.73
- Total Liabilities
- 3496.89
- Total Equity
- 2551.83
- Tangible Book Valueper Share Common Eq
- 155.95
- Period
- 2025
- Cashfrom Operating Activities
- 684.35
- Cashfrom Investing Activities
- -89.69
- Cashfrom Financing Activities
- -642.58
- Net Changein Cash
- -48.46
- Period
- 2024
- Total Revenue
- 4051.12
- Selling/ General/ Admin Expenses Total
- 1423.21
- Depreciation/ Amortization
- 220
- Other Operating Expenses Total
- 23.68
- Total Operating Expense
- 3725.44
- Operating Income
- 325.69
- Net Income Before Taxes
- -116.94
- Net Income
- -70.61
- Diluted Normalized EPS
- -0.32
- Period
- 2024
- Total Assets
- 5839.76
- Total Liabilities
- 3714.19
- Total Equity
- 2125.56
- Tangible Book Valueper Share Common Eq
- 116.33
- Period
- 2024
- Cashfrom Operating Activities
- 700.93
- Cashfrom Investing Activities
- -150.25
- Cashfrom Financing Activities
- -693.32
- Net Changein Cash
- -142.48
- Period
- 2023
- Total Revenue
- 3688.39
- Selling/ General/ Admin Expenses Total
- 1434.4
- Depreciation/ Amortization
- 242.56
- Other Operating Expenses Total
- 35.13
- Total Operating Expense
- 3561.48
- Operating Income
- 126.91
- Net Income Before Taxes
- -286.2
- Net Income
- -202.64
- Diluted Normalized EPS
- -23.62
- Period
- 2023
- Total Assets
- 6638.42
- Total Liabilities
- 4426.16
- Total Equity
- 2212.26
- Tangible Book Valueper Share Common Eq
- 125.73
- Period
- 2023
- Cashfrom Operating Activities
- 44.07
- Cashfrom Investing Activities
- 302.47
- Cashfrom Financing Activities
- -213.92
- Net Changein Cash
- 132.77
- Period
- 2022
- Total Revenue
- 3070.25
- Selling/ General/ Admin Expenses Total
- 1351.7
- Depreciation/ Amortization
- 230.46
- Other Operating Expenses Total
- 19.75
- Total Operating Expense
- 3607.08
- Operating Income
- -536.83
- Net Income Before Taxes
- -652.51
- Net Income
- -460.21
- Diluted Normalized EPS
- -30.4
- Period
- 2022
- Total Assets
- 6975.86
- Total Liabilities
- 4616.63
- Total Equity
- 2359.23
- Tangible Book Valueper Share Common Eq
- 139.03
- Period
- 2022
- Cashfrom Operating Activities
- -257.82
- Cashfrom Investing Activities
- -118.73
- Cashfrom Financing Activities
- 421.32
- Net Changein Cash
- 44.9
- Period
- 2021
- Total Revenue
- 3315.87
- Selling/ General/ Admin Expenses Total
- 1150.49
- Depreciation/ Amortization
- 201.72
- Other Operating Expenses Total
- 12.15
- Total Operating Expense
- 2876.59
- Operating Income
- 439.28
- Net Income Before Taxes
- 275.44
- Net Income
- 268.44
- Diluted Normalized EPS
- 27.05
- Period
- 2021
- Total Assets
- 7015.02
- Total Liabilities
- 4238.36
- Total Equity
- 2776.66
- Tangible Book Valueper Share Common Eq
- 187.06
- Period
- 2021
- Cashfrom Operating Activities
- 481.44
- Cashfrom Investing Activities
- -520.82
- Cashfrom Financing Activities
- -15.8
- Net Changein Cash
- -56.4
- Period
- 2020
- Total Revenue
- 2751.97
- Selling/ General/ Admin Expenses Total
- 907.9
- Depreciation/ Amortization
- 173.7
- Other Operating Expenses Total
- 14.06
- Total Operating Expense
- 2455.48
- Operating Income
- 296.49
- Net Income Before Taxes
- 54.68
- Net Income
- 36.39
- Diluted Normalized EPS
- 12.8
- Period
- 2020
- Total Assets
- 6151.73
- Total Liabilities
- 3624.32
- Total Equity
- 2527.42
- Tangible Book Valueper Share Common Eq
- 173.34
- Period
- 2020
- Cashfrom Operating Activities
- 204.79
- Cashfrom Investing Activities
- 1306.16
- Cashfrom Financing Activities
- -1709.45
- Net Changein Cash
- -183.66
- Period
- 2019
- Total Revenue
- 2178.37
- Selling/ General/ Admin Expenses Total
- 699.8
- Depreciation/ Amortization
- 117.39
- Other Operating Expenses Total
- 9.8
- Total Operating Expense
- 2007.58
- Operating Income
- 170.79
- Net Income Before Taxes
- 62.4
- Net Income
- 324.62
- Diluted Normalized EPS
- 7.62
- Period
- 2019
- Total Assets
- 7979.66
- Total Liabilities
- 5330.95
- Total Equity
- 2648.7
- Tangible Book Valueper Share Common Eq
- -26.53
- Period
- 2019
- Cashfrom Operating Activities
- 60.05
- Cashfrom Investing Activities
- -148.49
- Cashfrom Financing Activities
- 194.27
- Net Changein Cash
- 109.73
- Period
- 2025-03-31
- Total Revenue
- 1190.39
- Selling/ General/ Admin Expenses Total
- 222.86
- Depreciation/ Amortization
- 48.86
- Other Operating Expenses Total
- 250.69
- Total Operating Expense
- 1048.8
- Operating Income
- 141.59
- Net Income Before Taxes
- 106.38
- Net Income
- 82.19
- Diluted Normalized EPS
- 11.31
- Period
- 2025-03-31
- Total Assets
- 6048.73
- Total Liabilities
- 3496.89
- Total Equity
- 2551.83
- Tangible Book Valueper Share Common Eq
- 155.95
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 684.35
- Cashfrom Investing Activities
- -89.69
- Cashfrom Financing Activities
- -642.58
- Net Changein Cash
- -48.46
- Period
- 2024-12-31
- Total Revenue
- 1153.67
- Selling/ General/ Admin Expenses Total
- 215.64
- Depreciation/ Amortization
- 48.42
- Other Operating Expenses Total
- 247.59
- Total Operating Expense
- 994.21
- Operating Income
- 159.46
- Net Income Before Taxes
- 113.85
- Net Income
- 87.95
- Diluted Normalized EPS
- 9.77
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1201.11
- Selling/ General/ Admin Expenses Total
- 219.41
- Depreciation/ Amortization
- 50.52
- Other Operating Expenses Total
- 247.97
- Total Operating Expense
- 1019.7
- Operating Income
- 181.41
- Net Income Before Taxes
- 114.86
- Net Income
- 93.23
- Diluted Normalized EPS
- 10.46
- Period
- 2024-09-30
- Total Assets
- 5989.63
- Total Liabilities
- 3718.21
- Total Equity
- 2271.42
- Tangible Book Valueper Share Common Eq
- 124.08
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 418.2
- Cashfrom Investing Activities
- -39.19
- Cashfrom Financing Activities
- -409.31
- Net Changein Cash
- -30.38
- Period
- 2024-06-30
- Total Revenue
- 1087.5
- Selling/ General/ Admin Expenses Total
- 212.17
- Depreciation/ Amortization
- 48.59
- Other Operating Expenses Total
- 237.91
- Total Operating Expense
- 922.85
- Operating Income
- 164.65
- Net Income Before Taxes
- 85.17
- Net Income
- 70.2
- Diluted Normalized EPS
- 7.95
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1084.04
- Selling/ General/ Admin Expenses Total
- 199.17
- Depreciation/ Amortization
- 49.76
- Other Operating Expenses Total
- 248.55
- Total Operating Expense
- 921.77
- Operating Income
- 162.26
- Net Income Before Taxes
- 29.62
- Net Income
- 18.18
- Diluted Normalized EPS
- 2.54
- Period
- 2024-03-31
- Total Assets
- 5839.76
- Total Liabilities
- 3714.19
- Total Equity
- 2125.56
- Tangible Book Valueper Share Common Eq
- 116.33
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 700.93
- Cashfrom Investing Activities
- -150.25
- Cashfrom Financing Activities
- -693.32
- Net Changein Cash
- -142.48
- Period
- 2023-12-31
- Total Revenue
- 1005.77
- Selling/ General/ Admin Expenses Total
- 180.42
- Depreciation/ Amortization
- 49.44
- Other Operating Expenses Total
- 214.62
- Total Operating Expense
- 923.29
- Operating Income
- 82.48
- Net Income Before Taxes
- 8.98
- Net Income
- 49.67
- Diluted Normalized EPS
- -0.5
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Strides Pharma Science Technical
Moving Average
SMA
- 5 Day872.38
- 10 Day833.89
- 20 Day790.16
- 50 Day705.06
- 100 Day675.36
- 300 Day953.8
Strides Pharma Science Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shilpa Medicare
- 875.5
- -14.3
- -1.61
- 1003.2
- 518.4
- 8615.93
- Aarti Pharmalabs
- 859.95
- 19.1
- 2.27
- 948.8
- 521
- 7809.22
- Strides Pharma Science
- 829.85
- -14.85
- -1.76
- 901.75
- 412.71
- 7627.59
- Fdc
- 458.9
- 1.2
- 0.26
- 659
- 358.95
- 7480.93
- Supriya Lifescience
- 675
- 18.95
- 2.89
- 841.7
- 368.6
- 5400.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shilpa Medicare
- 92.85
- 3.78
- 3.27
- 5.17
- Aarti Pharmalabs
- 29.3
- 4.01
- -
- -
- Strides Pharma Science
- 22.39
- 3.08
- -1.22
- -1.07
- Fdc
- 28.58
- 3.34
- 13.26
- 14.75
- Supriya Lifescience
- 28.73
- 5.42
- 22.63
- 25.45
Strides Pharma Science Shareholding
Shareholding Pattern
*Promoter pledging: 14.71%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 22-May-25
- Audited Results & Final Dividend
- 30-Jan-25
- Quarterly Results
- 24-Oct-24
- Quarterly Results
- 29-Jul-24
- Quarterly Results
- 22-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 30-Oct-23
- Quarterly Results
- 25-Sept-23
- Scheme of Arrangement
- 02-Aug-23
- Quarterly Results
- 25-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 21-Mar-25
- 17-Feb-25
- POM
- 29-Nov-24
- 29-Oct-24
- POM
- 25-Sept-24
- 21-Aug-24
- AGM
- 10-Sept-24
- 08-Aug-24
- COM
- 28-Aug-23
- 25-May-23
- AGM
- 28-Jul-23
- 26-Jun-23
- POM
- 24-Mar-23
- 20-Feb-23
- POM
- 06-Feb-23
- 13-Jan-23
- EGM
- 09-Sept-22
- 24-May-22
- AGM
- 07-Apr-22
- 17-Feb-22
- EGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-25
- -
- -
- 4
- 22-May-24
- 09-Sept-24
- 09-Sept-24
- 2.5
- 21-Jul-23
- 04-Aug-23
- 04-Aug-23
- 1.5
- 27-May-21
- 06-Aug-21
- 05-Aug-21
- 2.5


